|
19 Sep 2019 |
PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial
|
|
18 Sep 2019 |
FDA Accepts Merck’s Biologics License Application (BLA) and Grants Priority Review for V920, the Company’s Investigational Vaccine for Ebola Zaire Virus
|
|
17 Sep 2019 |
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac™ Individualized Immunotherapy TG4050
|
|
12 Sep 2019 |
Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials
|
|
10 Sep 2019 |
Axon Announces Positive Results From Phase II ADAMANT Trial for AADvac1 in Alzheimer's Disease
|
|
10 Sep 2019 |
VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSK’s AS01B Adjuvant System in Recurrent Glioblastoma Patients
|
|
09 Sep 2019 |
Pfizer Announces Positive Preliminary Results from a Proof-of-Concept Phase 2 Study (B7471003) of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Otitis Media in Healthy Infants
|
|
05 Sep 2019 |
Largest Real-World Study of Immunotherapy Shows Men with Advanced Prostate Cancer with Low PSA had a Median Survival of Nearly Four Years after Treatment with PROVENGE® (sipuleucel-T)
|
|
04 Sep 2019 |
SutroVax Receives CARB-X Award for Up to $15 Million to Develop a Universal Vaccine to Prevent Group A Streptococcus Infections
|
|
04 Sep 2019 |
Janssen Announces U.S. FDA Breakthrough Therapy Designation for Investigational Prophylactic Vaccine for the Prevention of Respiratory Syncytial Virus in Older Adults
|
|
27 Aug 2019 |
Imcyse reports successful first-in-human Phase 1b study in type 1 diabetes with IMCY-0098
|
|
22 Aug 2019 |
Themis Bioscience Announces Exclusive License and Research Collaboration Agreement with MSD to Develop Vaccine Candidates
|
|
21 Aug 2019 |
Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy
|
|
20 Aug 2019 |
Tonix Pharmaceuticals Expands Preclinical Pipeline with Triple Reuptake Inhibitor, TNX-1600, for the Treatment of PTSD
|
|
20 Aug 2019 |
Vaxxilon Awarded CARB-X Grant to Advance Novel Prophylactic Vaccine to Prevent Klebsiella pneumoniae Infections
|
|
19 Aug 2019 |
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
|
|
19 Aug 2019 |
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia
|
|
14 Aug 2019 |
Gritstone Oncology Announces First Patient Dosed with SLATE, its “Off-The-Shelf” Neoantigen Immunotherapy
|
|
14 Aug 2019 |
Brain Cancer Patients Display Decreasing Tumor Biomarkers After Treatment with Novel Immunotherapy in AIVITA Biomedical's Phase 2 Clinical Trial
|
|
06 Aug 2019 |
Transfer from GSK and partnership with NIAID will enable Sabin to advance development of the candidate vaccines
|
|
05 Aug 2019 |
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
|
|
05 Aug 2019 |
SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast
|
|
31 Jul 2019 |
SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study
|
|
30 Jul 2019 |
New Startup Biotech Company Plans to Test Promising Herpes Vaccine for Both HSV-1 and HSV-2
|
|
29 Jul 2019 |
Inovio’s Cancer Immunotherapy (INO-5151) Targeting Prostate Cancer in Innovative Cancer Combination Trial
|
